| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 4 735-741, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
MS Bobola, SH Tseng, A Blank, MS Berger and JR Silber
Departments of Neurosurgery and Pathology, University of Washington, Seattle, Washington 98195, USA.
We have analyzed the sensitivity of 14 human medulloblastoma- and glioma-derived cell lines to the clinically used methylating agents temozolomide and streptozotocin. The cell lines responded similarly to these agents, displaying a 3-fold range in cytotoxicity, assessed as the 10% survival dose (LD10). The contribution of O6-methylguanine-DNA methyltransferase (MGMT) to resistance, measured as reduction in the LD10 by O6-benzylguanine (O6-BG), varied among the lines by 1 order of magnitude for both agents. However, in all MGMT-expressing lines, O6-BG eliminated a threshold dose that accounted for up to one-half of the LD10. The effect of O6-BG on the rate of killing varied 13-fold for temozolomide and 14-fold for streptozotocin. Some lines displayed two subpopulations with different rates of killing, with one subpopulation that comprised 20-60% of cells showing essentially no dependence of the rate of killing on MGMT. O6-BG increased the range of the LD10 for both agents. The persistent, heightened variability in cytotoxicity in the absence of MGMT, the lack of correlation between MGMT content of the lines and cytoxicity (LD10), and the lack of correlation between MGMT content and the contribution of MGMT to resistance (O6-BG-mediated reduction of the LD10) reflect the operation of resistance mechanisms other than MGMT. We also analyzed sensitivity to methyl methanesulfonate, observing little dependence of resistance on MGMT and persistent variability in cytotoxicity in the presence of O6-BG. We discuss the implications for clinical use of methylators and O6-BG.
This article has been cited by other articles:
|
|
 |
|
  J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al. Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report Clin. Cancer Res., November 15, 2007; 13(22): 6712 - 6718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bobola, S. Varadarajan, N. W. Smith, R. D. Goff, D. D. Kolstoe, A. Blank, B. Gold, and J. R. Silber Human Glioma Cell Sensitivity to the Sequence-Specific Alkylating Agent Methyl-Lexitropsin Clin. Cancer Res., January 15, 2007; 13(2): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Quinn, A. Desjardins, J. Weingart, H. Brem, M. E. Dolan, S. M. Delaney, J. Vredenburgh, J. Rich, A. H. Friedman, D. A. Reardon, et al. Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., October 1, 2005; 23(28): 7178 - 7187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Trivedi, K. H. Almeida, J. L. Fornsaglio, S. Schamus, and R. W. Sobol The Role of Base Excision Repair in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death Cancer Res., July 15, 2005; 65(14): 6394 - 6400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bobola, J. R. Silber, R. G. Ellenbogen, J. R. Geyer, A. Blank, and R. D. Goff O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines Clin. Cancer Res., April 1, 2005; 11(7): 2747 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bobola, M. J. Emond, A. Blank, E. H. Meade, D. D. Kolstoe, M. S. Berger, R. C. Rostomily, D. L. Silbergeld, A. M. Spence, and J. R. Silber Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy Clin. Cancer Res., December 1, 2004; 10(23): 7875 - 7883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Jaeckle, K. R. Hess, W.K. A. Yung, H. Greenberg, H. Fine, D. Schiff, I. F. Pollack, J. Kuhn, K. Fink, M. Mehta, et al. Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study J. Clin. Oncol., June 15, 2003; 21(12): 2305 - 2311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Silber, M. S. Bobola, A. Blank, K. D. Schoeler, P. D. Haroldson, M. B. Huynh, and D. D. Kolstoe The Apurinic/Apyrimidinic Endonuclease Activity of Ape1/Ref-1 Contributes to Human Glioma Cell Resistance to Alkylating Agents and Is Elevated by Oxidative Stress Clin. Cancer Res., September 1, 2002; 8(9): 3008 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wu, M. R. Kelley, W. K. Hansen, and W. J. Martin II Reduction of BCNU toxicity to lung cells by high-level expression of O6-methylguanine-DNA methyltransferase Am J Physiol Lung Cell Mol Physiol, April 1, 2001; 280(4): L755 - L761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bobola, M. S. Berger, R. G. Ellenbogen, T. S. Roberts, J. R. Geyer, and J. R. Silber O6-Methylguanine-DNA Methyltransferase in Pediatric Primary Brain Tumors: Relation to Patient and Tumor Characteristics Clin. Cancer Res., March 1, 2001; 7(3): 613 - 619. [Abstract] [Full Text]
|
|
|
|
|
|
H. S. Friedman, T. Kerby, and H. Calvert Temozolomide and Treatment of Malignant Glioma Clin. Cancer Res., July 1, 2000; 6(7): 2585 - 2597. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. L. Nutt, N. A. Loktionova, A. E. Pegg, A. F. Chambers, and J.g. Cairncross O6-Methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes Carcinogenesis, December 1, 1999; 20(12): 2361 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Tseng, M. S. Bobola, M. S. Berger, and J. R. Silber Characterization of paclitaxel (Taxol(R)) sensitivity in human glioma- and medulloblastoma-derived cell lines Neuro-oncol, April 1, 1999; 1(2): 101 - 108. [Abstract] [PDF]
|
|
|
|
|
|
J. R. Silber, A. Blank, M. S. Bobola, S. Ghatan, D. D. Kolstoe, and M. S. Berger O6-Methylguanine-DNA Methyltransferase-deficient Phenotype in Human Gliomas: Frequency and Time to Tumor Progression after Alkylating Agent-based Chemotherapy Clin. Cancer Res., April 1, 1999; 5(4): 807 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hampson, O. Humbert, P. Macpherson, G. Aquilina, and P. Karran Mismatch Repair Defects and O6-Methylguanine-DNA Methyltransferase Expression in Acquired Resistance to Methylating Agents in Human Cells J. Biol. Chem., November 7, 1997; 272(45): 28596 - 28606. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
